• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

26.53 +1.47 (+5.87%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,459,477
Open 26.17
Bid (Size) 27.10 (1,500)
Ask (Size) 27.40 (1,000)
Prev. Close 25.06
Today's Range 25.80 - 27.89
52wk Range 23.75 - 52.93
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Premarket Movers on Oct. 20, 2026: Gainers and Losers ↗
October 20, 2026
Via Chartmill
News headline image
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
October 20, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 49.9% below 52-week high
26.53
23.7552W Low 52.9352W High
1 Week 15.3% below 1-week high
24.691W Low 31.311W High

Rapport Therapeutics, Inc. - Common Stock (RAPP) traded between $23.75 and $52.93 over the past 52 weeks and last traded at $26.53, 49.9% below its 52-week high. Over the past week it ranged between $24.69 and $31.31.

Past 12 Months
-3.8%
-36.0%
-35.9%
-27.0%
-5.6%
+6.5%
1W -$1.04
1M -$14.94
3M -$14.85
6M -$9.83
YTD -$1.58
1Y +$1.63

RAPP was +6.5% over the past year, -27.0% over six months, -5.6% year to date, -3.8% in the last week.

12 Months vs Market
RAPP
+6.5%
DIA
+12.5%
SPY
+13.8%
QQQ
+15.2%
IWM
+12.0%

Over the past 12 months RAPP returned +6.5% versus DIA (Dow) +12.5%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 2.82× 3-mo avg
Today 1,459,477 3-mo avg 518.3K
1W
2.5M
1M
889.3K
3M
518.3K
6M
444.0K
YTD
407.2K
1Y
404.9K

RAPP most recently traded 1,459,477 shares against a 3-month average daily volume of 518.3K.

More News

Read More
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
September 02, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
August 31, 2026
Via The Motley Fool
Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines ↗
May 07, 2026
Via Chartmill
News headline image
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
August 24, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
August 05, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? ↗
July 12, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 07, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near ↗
April 27, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
April 21, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
April 01, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
March 09, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
January 07, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
December 22, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
December 22, 2025
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 05, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rapport Therapeutics, Inc. - Common Stock publicly traded?
Yes, Rapport Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Rapport Therapeutics, Inc. - Common Stock trade on?
Rapport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rapport Therapeutics, Inc. - Common Stock?
The ticker symbol for Rapport Therapeutics, Inc. - Common Stock is RAPP on the Nasdaq Stock Market
What is the current price of Rapport Therapeutics, Inc. - Common Stock?
The current price of Rapport Therapeutics, Inc. - Common Stock is 26.53
When was Rapport Therapeutics, Inc. - Common Stock last traded?
The last trade of Rapport Therapeutics, Inc. - Common Stock was at 10/22/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap